The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Updated efficacy and safety of JNJ-5322, a next-generation trispecific antibody, in R/R myeloma
Amrita Krishnan, MD, City of Hope, Duarte, CA, shares updated efficacy and safety results from a Phase I study (NCT05652335) evaluating JNJ-5322 (romantamig), a novel, next-generation BCMA×GPRC5D×CD3 trispecific antibody, in patients with relapsed/refractory (R/R) multiple myeloma (MM). Dr Krishnan notes that the data remain promising and that the agent offers the benefit of convenient administration in the outpatient setting. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So J&J5322, first of all, has an official name now, romantamig, and it is a tri-specific antibody targeting two antigens on the myeloma cell, BCMA and GPRC5D, and then it targets CD3 on the T-cell. And the results we presented are on a Phase one trial, a longer follow-up now than what was presented at ASCO. And what we show is that the response rate’s 100% in BCMA-naive patients...
So J&J5322, first of all, has an official name now, romantamig, and it is a tri-specific antibody targeting two antigens on the myeloma cell, BCMA and GPRC5D, and then it targets CD3 on the T-cell. And the results we presented are on a Phase one trial, a longer follow-up now than what was presented at ASCO. And what we show is that the response rate’s 100% in BCMA-naive patients. The median follow-up now is 14.4 months, and the 12-month PFS is over 80%.
In regards to toxicity, the toxicity profile seems favorable. The grade 3, grade 4 infections plateau after one year of treatment, and also the GPRC-related toxicities in terms of dysgeusia and weight loss seem significantly less than what we’ve seen with talquetamab, the single GPRC-targeting bispecific antibody.
So, you know, also just ease of use – it has a single step-up dose and a Q4-week dosing schedule. So in terms of efficacy, certainly very promising results. In terms of safety, also the signal seems very good. And in terms of options for outpatient dosing and convenience for patients, also it really looks like it has some exciting options.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
